KUMAMOTO University

R

研究業績RESEARCH ACHIEVEMENTS

  1. Ndongwe TP, Adedeji AO, Michailidis E, Ong YT, Hachiya A, Marchand B, Ryan EM, Rai DK, Kirby KA, Whatley AS, Burke DH, Johnson M, Ding S, Zheng YM, Liu SL, Kodama E, Delviks-Frankenberry KA, Pathak VK, Mitsuya H, Parniak MA, Singh K, Sarafianos SG.

    Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase.

    Nucleic Acids Res. 2012 Jan;40(1):345-59. doi: 10.1093/nar/gkr694. Epub 2011 Sep 8. PMID: 21908397; PMCID: PMC3245923.

  2. Sohl CD, Singh K, Kasiviswanathan R, Copeland WC, Mitsuya H, Sarafianos SG, Anderson KS.

    Mechanism of interaction of human mitochondrial DNA polymerase γ with the novel nucleoside reverse transcriptase inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine indicates a low potential for host toxicity.

    Antimicrob Agents Chemother. 2012 Mar;56(3):1630-4. doi: 10.1128/AAC.05729-11. Epub 2011 Dec 12. PMID: 22155823; PMCID: PMC3294915.

  3. Ghosh AK, Anderson DD, Weber IT, Mitsuya H.

    Enhancing protein backbone binding–a fruitful concept for combating drug-resistant HIV.

    Angew Chem Int Ed Engl. 2012 Feb 20;51(8):1778-802. doi: 10.1002/anie.201102762. Epub 2012 Jan 31. PMID: 22290878.

  4. Ghosh AK, Chapsal BD, Steffey M, Agniswamy J, Wang YF, Amano M, Weber IT, Mitsuya H.

    Substituent effects on P2-cyclopentyltetrahydrofuranyl urethanes: design, synthesis, and X-ray studies of potent HIV-1 protease inhibitors.

    Bioorg Med Chem Lett. 2012 Mar 15;22(6):2308-11. doi: 10.1016/j.bmcl.2012.01.061. Epub 2012 Feb 2. PMID: 22364812; PMCID: PMC3433276.

  5. Sohl CD, Kasiviswanathan R, Kim J, Pradere U, Schinazi RF, Copeland WC, Mitsuya H, Baba M, Anderson KS.

    Balancing antiviral potency and host toxicity: identifying a nucleotide inhibitor with an optimal kinetic phenotype for HIV-1 reverse transcriptase.

    Mol Pharmacol. 2012 Jul;82(1):125-33. doi: 10.1124/mol.112.078758. Epub 2012 Apr 18. PMID: 22513406; PMCID: PMC3382833.

  6. Maeda K, Das D, Nakata H, Mitsuya H.

    CCR5 inhibitors: emergence, success, and challenges.

    Expert Opin Emerg Drugs. 2012 Jun;17(2):135-45. doi: 10.1517/14728214.2012.673584. Epub 2012 Apr 25. PMID: 22533737.

  7. Murphey-Corb M, Rajakumar P, Michael H, Nyaundi J, Didier PJ, Reeve AB, Mitsuya H, Sarafianos SG, Parniak MA.

    Response of simian immunodeficiency virus to the novel nucleoside reverse transcriptase inhibitor 4′-ethynyl-2-fluoro-2′-deoxyadenosine in vitro and in vivo.

    Antimicrob Agents Chemother. 2012 Sep;56(9):4707-12. doi: 10.1128/AAC.00723-12. Epub 2012 Jun 19. PMID: 22713337; PMCID: PMC3421895.

  8. Aoki M, Danish ML, Aoki-Ogata H, Amano M, Ide K, Das D, Koh Y, Mitsuya H.

    Loss of the protease dimerization inhibition activity of tipranavir (TPV) and its association with the acquisition of resistance to TPV by HIV-1.

    J Virol. 2012 Dec;86(24):13384-96. doi: 10.1128/JVI.07234-11. Epub 2012 Sep 26. PMID: 23015723; PMCID: PMC3503118.

  9. Okuno Y, Tatetsu H, Nosaka K, Mitsuya H.

    Three cases of aggressive natural killer cell leukemia with a lethal hemorrhagic complication.

    J Clin Exp Hematop. 2012;52(2):101-6. doi: 10.3960/jslrt.52.101. PMID: 23037625.

  10. Douceron E, Kaidarova Z, Miyazato P, Matsuoka M, Murphy EL, Mahieux R.

    HTLV-2 APH-2 expression is correlated with proviral load but APH-2 does not promote lymphocytosis.

    J Infect Dis. 2012 Jan 1;205(1):82-6. doi: 10.1093/infdis/jir708. Epub 2011 Nov 7. PMID: 22065675; PMCID: PMC3242747.

  11. Sugata K, Satou Y, Yasunaga J, Hara H, Ohshima K, Utsunomiya A, Mitsuyama M, Matsuoka M.

    HTLV-1 bZIP factor impairs cell-mediated immunity by suppressing production of Th1 cytokines.

    Blood. 2012 Jan 12;119(2):434-44. doi: 10.1182/blood-2011-05-357459. Epub 2011 Nov 28. PMID: 22123848; PMCID: PMC3257009.

  12. Kawano Y, Fujiwara S, Wada N, Izaki M, Yuki H, Okuno Y, Iyama K, Yamasaki H, Sakai A, Mitsuya H, Hata H.

    Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide.

    Int J Oncol. 2012 Sep;41(3):876-84. doi: 10.3892/ijo.2012.1545. Epub 2012 Jul 4. PMID: 22766978; PMCID: PMC3582943.

  13. Edwards CK 3rd, Green JS, Volk HD, Schiff M, Kotzin BL, Mitsuya H, Kawaguchi T, Sakata KM, Cheronis J, Trollinger D, Bankaitis-Davis D, Dinarello CA, Norris DA, Bevilacqua MP, Fujita M, Burmester GR.

    Combined anti-tumor necrosis factor-α therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy alone.

    Front Immunol. 2012 Dec 4;3:366. doi: 10.3389/fimmu.2012.00366. PMID: 23264777; PMCID: PMC3525111.

  14. Michailidis E, Singh K, Ryan EM, Hachiya A, Ong YT, Kirby KA, Marchand B, Kodama EN, Mitsuya H, Parniak MA, Sarafianos SG.

    Effect of translocation defective reverse transcriptase inhibitors on the activity of N348I, a connection subdomain drug resistant HIV-1 reverse transcriptase mutant.

    Cell Mol Biol (Noisy-le-grand). 2012 Dec 22;58(1):187-95. PMID: 23273211; PMCID: PMC3551986.

CONTACT US

C

  • 患者様へ

    外来診療の方は外来予約センターより
    ご予約をお願いいたします。
    外来予約センター

  • 学生・研修医・医療関係者の方へ

    TEL
    096-373-5156
    FAX
    096-373-5158
    Mail
    nikyo@kumamoto-u.ac.jp
Copyright 2019 KUMAMOTO University HRI All Rights Reserved.